DDW 2018: Infliximab Appears to Be Superior to Adalimumab in Maintaining Remission of Ulcerative Colitis
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Only registered members have full access to PracticeUpdate content.